CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

Kelly N. Fitzgerald; Andres E. Quesada; Gottfried von Keudell; Sandeep Raj; Natasha E. Lewis; Ahmet Dogan; Gilles Salles; M. Lia Palomba

doi:10.1080/10428194.2021.1992622

CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

Kelly N. Fitzgerald, Andres E. Quesada, Gottfried von Keudell, Sandeep Raj, Natasha E. Lewis, Ahmet Dogan, Gilles Salles, M. Lia Palomba

Hematopathology

Research output: Contribution to journal › Letter › peer-review

7 Scopus citations

Original language	English (US)
Pages (from-to)	751-754
Number of pages	4
Journal	Leukemia and Lymphoma
Volume	63
Issue number	3
DOIs	https://doi.org/10.1080/10428194.2021.1992622
State	Published - 2022

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2021.1992622

Cite this

@article{11b61b941df84f18ae0ca17a5040067f,

title = "CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas",

author = "Fitzgerald, {Kelly N.} and Quesada, {Andres E.} and {von Keudell}, Gottfried and Sandeep Raj and Lewis, {Natasha E.} and Ahmet Dogan and Gilles Salles and Palomba, {M. Lia}",

note = "Funding Information: We would like to thank the Janice Stanton Fund for supporting this work. This work was supported in part through the NIH/NCI Cancer Center Support Grant [P30 CA008748] and MSK Lymphoma SPORE [P50 CA192937] (A.D.) and Farmer Family Foundation (A.D.). Funding Information: Ahmet Dogan reports personal fees from Corvus Pharmaceuticals, Physicians{\textquoteright} Education Resource, Seattle Genetics, Takeda, Roche, EUSAPharma, PeerView, and research support from Roche and Takeda. ",

year = "2022",

doi = "10.1080/10428194.2021.1992622",

language = "English (US)",

volume = "63",

pages = "751--754",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

AU - Fitzgerald, Kelly N.

AU - Quesada, Andres E.

AU - von Keudell, Gottfried

AU - Raj, Sandeep

AU - Lewis, Natasha E.

AU - Dogan, Ahmet

AU - Salles, Gilles

AU - Palomba, M. Lia

N1 - Funding Information: We would like to thank the Janice Stanton Fund for supporting this work. This work was supported in part through the NIH/NCI Cancer Center Support Grant [P30 CA008748] and MSK Lymphoma SPORE [P50 CA192937] (A.D.) and Farmer Family Foundation (A.D.). Funding Information: Ahmet Dogan reports personal fees from Corvus Pharmaceuticals, Physicians’ Education Resource, Seattle Genetics, Takeda, Roche, EUSAPharma, PeerView, and research support from Roche and Takeda.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85121790784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121790784&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.1992622

DO - 10.1080/10428194.2021.1992622

M3 - Letter

C2 - 34949132

AN - SCOPUS:85121790784

SN - 1042-8194

VL - 63

SP - 751

EP - 754

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -

CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this